An update from Insulet ( (PODD) ) is now available.
On March 18, 2025, Insulet Corporation announced the pricing of $450 million in senior unsecured notes due 2033, with an annual interest rate of 6.50%. The proceeds, estimated at $444.4 million, will be used to finance the redemption of existing convertible senior notes, cover offering-related expenses, and for general corporate purposes. The private placement is expected to close on March 20, 2025, and the notes are offered to qualified institutional buyers and non-U.S. persons under specific regulations.
More about Insulet
Insulet Corporation, headquartered in Massachusetts, is a medical device company focused on simplifying life for people with diabetes through its Omnipod product platform. The Omnipod Insulin Management System offers an alternative to traditional insulin delivery methods, featuring a wearable design that provides continuous insulin delivery without needles. Insulet’s Omnipod 5 Automated Insulin Delivery System integrates with a glucose monitor for blood sugar management and can be controlled via smartphone or the Omnipod Controller. The company is also expanding its technology platform for non-insulin drug delivery.
YTD Price Performance: 1.86%
Average Trading Volume: 682,822
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $17.94B
See more data about PODD stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com